Clinical trials: Metastatic Renal Cancer
Clear-Cell Renal Cell Carcinoma
Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
Study 516-008 is an open-label Phase 1 dose escalation/Phase 1b dose expansion study evaluating the safety and tolerability, clinical activity, and PK of sitravatinib in combination with nivolumab and ipilimumab for the treatment…
- Trial name
- NCT04518046
- Testing
- Sitravatinib, Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Mirati Therapeutics Inc.
Renal Cell Carcinoma
A Post Marketing Surveillance As Required By Philippine Food And Drug Administration
This is a post marketing surveillance which determines the safety profile of the product to Filipinos. This is a FDA requirement for registration.
- Trial name
- NCT01781442
- Testing
- Temsirolimus
- Sponsor
- Pfizer
Liver Metastases, Liver Metastasis Colon Cancer
DNX-2440 for Resectable Colorectal Liver Metastasis
The purpose of this study is to test an experimental oncolytic adenovirus called DNX-2440 in patients with resectable multifocal (≥ 2 lesions) liver metastasis, who are scheduled to have curative-intent liver resection surgery.
- Conditions
- Liver Metastases, Liver Metastasis Colon Cancer, Colorectal Cancer, Breast Cancer
- Trial name
- NCT04714983
- Testing
- DNX-2440
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- DNAtrix, Inc.
Metastatic Breast Cancer, Advanced Breast Cancer
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib.
- Conditions
- Metastatic Breast Cancer, Advanced Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Renal Cell Cancer
- Trial name
- NCT00428220
- Testing
- sunitinib
- Where
- 113 sites in United States, Argentina and 15 more
- Volunteers
- 223 people
- Sponsor
- Pfizer
Renal Cell Carcinoma, Kidney Cancer
A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread
Patients with non-surgical or renal cell carcinoma that has spread who are starting treatment for the first time with Yervoy and Opdivo in the real world
- Trial name
- NCT03663946
- Testing
- Non-Interventional
- Where
- Japan
- Volunteers
- 81 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Renal Cell Carcinoma
RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib
To assess whether daily treatment with RAD001 could slow the growth and spread of metastatic carcinoma of the kidney. The safety of RAD001 was also to be studied in this trial.
- Trial name
- RECORD-1 (NCT00410124)
- Testing
- RAD001
- Where
- 93 sites in United States, Australia and 8 more
- Volunteers
- 416 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Renal Cell Carcinoma (mRCC)
Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
Patients with metastatic renal cell carcinoma (mRCC) who failed first-line therapy with sunitinib or pazopanib was treated with everolimus. Efficacy and safety of everolimus was evaluated in these patients.
- Trial name
- NCT01514448
- Testing
- Everolimus (RAD001)
- Where
- 13 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Tumor, Advanced Solid Tumor
A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T
As a phase I clinical research，this study plans to evaluate the safety and tolerability of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic solid tumors, and obtain recommended doses and infusion…
- Conditions
- Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer
- Trial name
- NCT05468190
- Testing
- CD70 CAR-T cells
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Metastatic Renal Cell Carcinoma
Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.
OPTIMISE is designed to provide knowledge regarding the use of Sunitinib as 1st line treatment and 2nd line treatment selected (Sunitinib-different sequence) with respect to efficacy outcomes, adverse events, and health related…
- Trial name
- OPTIMISE (NCT03140176)
- Testing
- Sunitinib
- Where
- 8 sites in Algeria, Egypt and 2 more
- Volunteers
- 77 people
- Sponsor
- Pfizer
Renal Cell Carcinoma
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma
- Trial name
- CheckMate 9ER (NCT03141177)
- Testing
- Nivolumab, Cabozantinib, Sunitinib
- Where
- 135 sites in United States, Argentina and 16 more
- Volunteers
- 701 people
- Sponsor
- Bristol-Myers Squibb
Carcinoma, Renal Cell
ATN-161 in Advanced Renal Cell Cancer
The purpose of this study is to determine an active dose of ATN-161 for future studies while establishing preliminary evidence of effectiveness in patients with renal cell cancer.
- Trial name
- NCT00131651
- Testing
- ATN-161
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Attenuon
Breast Neoplasms, Ovarian Neoplasms
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
The primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers.
- Conditions
- Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms
- Trial name
- NCT00120939
- Testing
- Motexafin Gadolinium
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Pharmacyclics LLC.
Metastatic Renal Cell Carcinoma
PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma
To evaluate the combination of PF-04856884 (CVX-060) in combination with Axitinib (AG-013736) in patients that have received one prior systemic regimen for metastatic renal cell carcinoma (mRCC) vs. axitinib alone.
- Trial name
- NCT01441414
- Testing
- PF-04856884, Axitinib (AG-013736)
- Where
- 29 sites in United States, Czechia
- Volunteers
- 18 people
- Sponsor
- Pfizer
Mesothelioma, Glioblastoma
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Conditions
- Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT04913337
- Testing
- NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
- Where
- 27 sites in United States, South Korea and 1 more
- Volunteers
- 179 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Metastatic Clear Cell Renal Cell Carcinoma
A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
To compare the progression free survival of LY2510924 plus sunitinib therapy versus sunitinib in the first-line setting for patients with metastatic clear-cell renal cell carcinoma.
- Trial name
- NCT01391130
- Testing
- LY2510924, Sunitinib
- Where
- 21 sites in United States
- Volunteers
- 110 people
- Sponsor
- Eli Lilly and Company
Metastatic Renal Cell Carcinoma
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
The primary objective of the phase III study is to investigate whether IMA901 can prolong overall survival in patients with metastatic and/or locally advanced renal cell carcinoma (RCC) when added to standard first-line therapy…
- Trial name
- NCT01265901
- Testing
- Sunitinib, GM-CSF, Cyclophosphamide
- Where
- 105 sites in United States, France and 9 more
- Volunteers
- 339 people
- Sponsor
- Immatics Biotechnologies GmbH
Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
This is a Phase 1 dose escalation study using a 3+3 study design, followed by a phase 1b expansion study. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced…
- Trial name
- TRAVERSE (NCT04696731)
- Testing
- ALLO-316, ALLO-647, Fludarabine
- Where
- 10 sites in United States
- Volunteers
- 120 people
- Sponsor
- Allogene Therapeutics
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
ER+ Breast Cancer, Ovarian Cancer
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
This Phase 1b is a dose escalation, MTD expansion and cohort expansions study to assess the safety and tolerability of a combination of NAP with durvalumab in subjects with selected advanced or metastatic solid tumors.
- Conditions
- ER+ Breast Cancer, Ovarian Cancer, Cervical Squamous Cell Carcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT03983954
- Testing
- Obinutuzumab, naptumomab estafenatox and durvalumab, Naptumomab estafenatox and durvalumab
- Where
- 9 sites in India, Israel
- Volunteers
- 120 people
- Sponsor
- NeoTX Therapeutics Ltd.
Kidney Cancer, Renal Cell Carcinoma
Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer
This is an international, open label, randomized phase 3 trial in which patients with surgically removable kidney cancer will be randomly selected post-operatively to receive adjuvant treatment with autologous HSPPC-96 or no…
- Trial name
- NCT00126178
- Testing
- HSPPC-96
- Where
- 7 sites in United States, Canada
- Volunteers
- 600 people
- Sponsor
- Agenus Inc.